- Conditions
- Heart Diseases, Heart Failure, Heart Defects, Congenital
- Interventions
- SherpaPak Cardiac Transport System
- Device
- Lead sponsor
- Paragonix Technologies
- Industry
- Eligibility
- Not listed
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 17
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Gainesville, Florida + 13 more
Location Directory
Clinical trials in Jacksonville, Florida
This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7646
Shown on this page
12
Current sort
Recently updated
Location scope
Jacksonville, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 685–696 of 7,646 matching trials in Jacksonville, FL.
Live ClinicalTrials.gov results.
Institutions in Jacksonville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
- Interventions
- Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 424
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Axatilimab, Ruxolitinib, Corticosteroids
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Lupus Nephritis
- Interventions
- ianalumab s.c. q4w, ianalumab s.c. q12w, placebo s.c.
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • La Palma, California • Orange, California + 20 more
- Conditions
- Prosthetic-joint Infection
- Interventions
- VT-X7 Treatment System
- Combination Product
- Lead sponsor
- Osteal Therapeutics, Inc.
- Industry
- Eligibility
- 22 Years to 84 Years
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Los Angeles, California • Grand Junction, Colorado + 11 more
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- PF-06801591, Bacillus Calmette-Guerin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 24 more
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 76
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
- Conditions
- Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 50
- States / cities
- Fresno, California • Irvine, California • Los Alamitos, California + 43 more
- Conditions
- Prostate Carcinoma
- Interventions
- Best Practice, Computed Tomography, Electronic Health Record Review, Imaging Procedure, Questionnaire Administration, Radiation Therapy
- Other · Procedure · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
- Conditions
- Degenerative Disc Disease
- Interventions
- IDCT (rebonuputemcel), Sham (No Treatment)
- Biological · Other
- Lead sponsor
- DiscGenics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
- Conditions
- Pleural Malignant Mesothelioma
- Interventions
- Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
- Conditions
- Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL), Relapsed/Refractory Waldenström Macroglobulinemia (WM), Relapsed/Refractory Marginal Zone Lymphoma (MZL), Relapsed/Refractory Follicular Lymphoma (FL)
- Interventions
- APG-3288
- Drug
- Lead sponsor
- Ascentage Pharma Group Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Jacksonville, Florida • Grand Rapids, Michigan + 2 more